22 March 2018

TIKOMED PRESENTS IBSOLVMIR AT BIO EUROPE

IBsolvMIR is TikoMed’s original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that occurs when transplanted cells enter the bloodstream and come in contact with blood. IBsolvMIR has been documented to be a very safe drug and has shown efficacy in a Phase 2 study. TikoMed will now focus efforts on partnering strategy in order to bring the drug to the market.
At BIO Europe, Adam Bruce, founder of TikoMed presented development status and partner strategy for the project.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
31 July 2018
TIKOMED is looking for a business project manager with great administrative skills
We are looking for you who are driven, focused and known to get things done.…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
SEE MORE